JPH09500004A - 動物トランスジェニック幹細胞の単離、選択、および増殖 - Google Patents
動物トランスジェニック幹細胞の単離、選択、および増殖Info
- Publication number
- JPH09500004A JPH09500004A JP6522943A JP52294394A JPH09500004A JP H09500004 A JPH09500004 A JP H09500004A JP 6522943 A JP6522943 A JP 6522943A JP 52294394 A JP52294394 A JP 52294394A JP H09500004 A JPH09500004 A JP H09500004A
- Authority
- JP
- Japan
- Prior art keywords
- gene
- cells
- stem cells
- selectable marker
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000000130 stem cell Anatomy 0.000 title claims abstract description 111
- 241001465754 Metazoa Species 0.000 title claims abstract description 40
- 230000009261 transgenic effect Effects 0.000 title claims description 23
- 238000002955 isolation Methods 0.000 title claims description 20
- 210000004027 cell Anatomy 0.000 claims abstract description 221
- 239000003550 marker Substances 0.000 claims abstract description 102
- 230000014509 gene expression Effects 0.000 claims abstract description 50
- 230000004083 survival effect Effects 0.000 claims abstract description 7
- 238000012258 culturing Methods 0.000 claims abstract description 6
- 108090000623 proteins and genes Proteins 0.000 claims description 98
- 238000000034 method Methods 0.000 claims description 74
- 101710126211 POU domain, class 5, transcription factor 1 Proteins 0.000 claims description 30
- 239000012634 fragment Substances 0.000 claims description 25
- 102100035423 POU domain, class 5, transcription factor 1 Human genes 0.000 claims description 19
- 230000002068 genetic effect Effects 0.000 claims description 19
- 239000013598 vector Substances 0.000 claims description 19
- 210000004102 animal cell Anatomy 0.000 claims description 15
- 210000001671 embryonic stem cell Anatomy 0.000 claims description 13
- 230000012010 growth Effects 0.000 claims description 11
- 210000002459 blastocyst Anatomy 0.000 claims description 10
- 230000000694 effects Effects 0.000 claims description 10
- 238000001890 transfection Methods 0.000 claims description 10
- 210000003981 ectoderm Anatomy 0.000 claims description 8
- 230000001105 regulatory effect Effects 0.000 claims description 8
- 108700023863 Gene Components Proteins 0.000 claims description 7
- 108010091358 Hypoxanthine Phosphoribosyltransferase Proteins 0.000 claims description 7
- 210000004602 germ cell Anatomy 0.000 claims description 7
- 210000001778 pluripotent stem cell Anatomy 0.000 claims description 7
- 102000018251 Hypoxanthine Phosphoribosyltransferase Human genes 0.000 claims description 6
- 108010025815 Kanamycin Kinase Proteins 0.000 claims description 6
- 230000003115 biocidal effect Effects 0.000 claims description 6
- 210000002257 embryonic structure Anatomy 0.000 claims description 5
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims description 5
- 210000001161 mammalian embryo Anatomy 0.000 claims description 5
- 229960004927 neomycin Drugs 0.000 claims description 5
- 230000004936 stimulating effect Effects 0.000 claims description 5
- 239000003242 anti bacterial agent Substances 0.000 claims description 4
- 239000003102 growth factor Substances 0.000 claims description 4
- 230000006698 induction Effects 0.000 claims description 4
- 238000012423 maintenance Methods 0.000 claims description 4
- 210000000287 oocyte Anatomy 0.000 claims description 4
- 231100000331 toxic Toxicity 0.000 claims description 4
- 230000002588 toxic effect Effects 0.000 claims description 4
- 229930193140 Neomycin Natural products 0.000 claims description 3
- 108700020796 Oncogene Proteins 0.000 claims description 3
- 241000700584 Simplexvirus Species 0.000 claims description 3
- 102000006601 Thymidine Kinase Human genes 0.000 claims description 3
- 108020004440 Thymidine kinase Proteins 0.000 claims description 3
- 108091023040 Transcription factor Proteins 0.000 claims description 3
- 102000040945 Transcription factor Human genes 0.000 claims description 3
- 230000001413 cellular effect Effects 0.000 claims description 3
- 238000004520 electroporation Methods 0.000 claims description 3
- 210000002514 epidermal stem cell Anatomy 0.000 claims description 3
- 239000013604 expression vector Substances 0.000 claims description 3
- 238000002347 injection Methods 0.000 claims description 3
- 239000007924 injection Substances 0.000 claims description 3
- 238000001638 lipofection Methods 0.000 claims description 3
- 239000000758 substrate Substances 0.000 claims description 3
- 239000013603 viral vector Substances 0.000 claims description 3
- 206010010144 Completed suicide Diseases 0.000 claims description 2
- 102000009465 Growth Factor Receptors Human genes 0.000 claims description 2
- 108010009202 Growth Factor Receptors Proteins 0.000 claims description 2
- 230000001580 bacterial effect Effects 0.000 claims description 2
- 210000004369 blood Anatomy 0.000 claims description 2
- 239000008280 blood Substances 0.000 claims description 2
- -1 bombardment missile Substances 0.000 claims description 2
- 230000030833 cell death Effects 0.000 claims description 2
- 230000011712 cell development Effects 0.000 claims description 2
- 230000002710 gonadal effect Effects 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- 210000001178 neural stem cell Anatomy 0.000 claims description 2
- 230000006798 recombination Effects 0.000 claims description 2
- 238000005215 recombination Methods 0.000 claims description 2
- 210000001988 somatic stem cell Anatomy 0.000 claims description 2
- 210000002444 unipotent stem cell Anatomy 0.000 claims description 2
- 108700026220 vif Genes Proteins 0.000 claims description 2
- 101710128836 Large T antigen Proteins 0.000 claims 2
- 238000012239 gene modification Methods 0.000 claims 2
- 230000005017 genetic modification Effects 0.000 claims 2
- 235000013617 genetically modified food Nutrition 0.000 claims 2
- 101150118155 Cd34 gene Proteins 0.000 claims 1
- 101150072261 large T gene Proteins 0.000 claims 1
- 230000002463 transducing effect Effects 0.000 claims 1
- 210000002242 embryoid body Anatomy 0.000 description 27
- 230000004069 differentiation Effects 0.000 description 16
- 210000001519 tissue Anatomy 0.000 description 14
- 239000001963 growth medium Substances 0.000 description 10
- 238000010186 staining Methods 0.000 description 9
- 241000699666 Mus <mouse, genus> Species 0.000 description 8
- 208000012868 Overgrowth Diseases 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 238000013459 approach Methods 0.000 description 5
- 102000005936 beta-Galactosidase Human genes 0.000 description 5
- 108010005774 beta-Galactosidase Proteins 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 230000018109 developmental process Effects 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 239000013612 plasmid Substances 0.000 description 5
- 238000004113 cell culture Methods 0.000 description 4
- 230000008030 elimination Effects 0.000 description 4
- 238000003379 elimination reaction Methods 0.000 description 4
- 230000002688 persistence Effects 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 230000008685 targeting Effects 0.000 description 4
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 3
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 102000007568 Proto-Oncogene Proteins c-fos Human genes 0.000 description 3
- 108010071563 Proto-Oncogene Proteins c-fos Proteins 0.000 description 3
- 108700019146 Transgenes Proteins 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 210000002308 embryonic cell Anatomy 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 230000010354 integration Effects 0.000 description 3
- 238000004114 suspension culture Methods 0.000 description 3
- 108091026890 Coding region Proteins 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 108091005904 Hemoglobin subunit beta Proteins 0.000 description 2
- 102000004058 Leukemia inhibitory factor Human genes 0.000 description 2
- 108090000581 Leukemia inhibitory factor Proteins 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 241001045988 Neogene Species 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 230000024245 cell differentiation Effects 0.000 description 2
- 230000022534 cell killing Effects 0.000 description 2
- 210000004748 cultured cell Anatomy 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 230000013020 embryo development Effects 0.000 description 2
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 description 2
- 229960002963 ganciclovir Drugs 0.000 description 2
- 230000001744 histochemical effect Effects 0.000 description 2
- 230000006801 homologous recombination Effects 0.000 description 2
- 238000002744 homologous recombination Methods 0.000 description 2
- 238000002513 implantation Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 238000004264 monolayer culture Methods 0.000 description 2
- 230000000877 morphologic effect Effects 0.000 description 2
- 101150091879 neo gene Proteins 0.000 description 2
- 238000009806 oophorectomy Methods 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 230000008488 polyadenylation Effects 0.000 description 2
- 230000035935 pregnancy Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- 230000000392 somatic effect Effects 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 238000011830 transgenic mouse model Methods 0.000 description 2
- WZUVPPKBWHMQCE-XJKSGUPXSA-N (+)-haematoxylin Chemical compound C12=CC(O)=C(O)C=C2C[C@]2(O)[C@H]1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-XJKSGUPXSA-N 0.000 description 1
- BRZYSWJRSDMWLG-DJWUNRQOSA-N (2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2s,3r,4r,5s,6r)-3-amino-4,5-dihydroxy-6-[(1r)-1-hydroxyethyl]oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H]([C@@H](C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-DJWUNRQOSA-N 0.000 description 1
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 239000011547 Bouin solution Substances 0.000 description 1
- 238000011749 CBA mouse Methods 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 206010011732 Cyst Diseases 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Natural products C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 1
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 1
- 102100021519 Hemoglobin subunit beta Human genes 0.000 description 1
- 101000756632 Homo sapiens Actin, cytoplasmic 1 Proteins 0.000 description 1
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 1
- 102000005755 Intercellular Signaling Peptides and Proteins Human genes 0.000 description 1
- 108010070716 Intercellular Signaling Peptides and Proteins Proteins 0.000 description 1
- 102000004889 Interleukin-6 Human genes 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 102000010781 Interleukin-6 Receptors Human genes 0.000 description 1
- 108010038501 Interleukin-6 Receptors Proteins 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 102000002584 Octamer Transcription Factor-3 Human genes 0.000 description 1
- 108010068425 Octamer Transcription Factor-3 Proteins 0.000 description 1
- 102000043276 Oncogene Human genes 0.000 description 1
- 101710160107 Outer membrane protein A Proteins 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 102000009523 Transcription Factor 4 Human genes 0.000 description 1
- 108010048992 Transcription Factor 4 Proteins 0.000 description 1
- 108700029229 Transcriptional Regulatory Elements Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- VJBCNMFKFZIXHC-UHFFFAOYSA-N azanium;2-(4-methyl-5-oxo-4-propan-2-yl-1h-imidazol-2-yl)quinoline-3-carboxylate Chemical group N.N1C(=O)C(C(C)C)(C)N=C1C1=NC2=CC=CC=C2C=C1C(O)=O VJBCNMFKFZIXHC-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000001588 bifunctional effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 208000031513 cyst Diseases 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000012224 gene deletion Methods 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 210000000777 hematopoietic system Anatomy 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 229940100601 interleukin-6 Drugs 0.000 description 1
- 101150066555 lacZ gene Proteins 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 230000016089 mRNA destabilization Effects 0.000 description 1
- 230000008774 maternal effect Effects 0.000 description 1
- 230000013011 mating Effects 0.000 description 1
- 210000003716 mesoderm Anatomy 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 238000001531 micro-dissection Methods 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 238000004091 panning Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000007639 printing Methods 0.000 description 1
- 230000005522 programmed cell death Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 238000012421 spiking Methods 0.000 description 1
- 230000023895 stem cell maintenance Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 230000030968 tissue homeostasis Effects 0.000 description 1
- 238000012250 transgenic expression Methods 0.000 description 1
- 230000010474 transient expression Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000014621 translational initiation Effects 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 230000001018 virulence Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
- C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
- C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/873—Techniques for producing new embryos, e.g. nuclear transfer, manipulation of totipotent cells or production of chimeric embryos
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0618—Cells of the nervous system
- C12N5/0623—Stem cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/02—Animal zootechnically ameliorated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/02—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from embryonic cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
- C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
- C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/44—Vectors comprising a special translation-regulating system being a specific part of the splice mechanism, e.g. donor, acceptor
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Plant Pathology (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Environmental Sciences (AREA)
- Developmental Biology & Embryology (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Biodiversity & Conservation Biology (AREA)
- Animal Husbandry (AREA)
- Neurosurgery (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Bag Frames (AREA)
- Saccharide Compounds (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.動物幹細胞を単離するおよび/または富化するおよび/または選択的に増殖 する方法であって、該方法は、細胞の生存の助けとなる培養条件下で、該細胞の 供給源を維持する工程を包含し、該細胞の供給源が、(a)所望の幹細胞および(b) 幹細胞以外の細胞で特異な発現が可能な選択マーカーを含む細胞を包含すること で特徴づけられ、それにより、該選択マーカーの特異な発現が、該所望の幹細胞 の選択的な単離および/または生存および/または分割を生じる、方法。 2.前記所望の幹細胞が、単能性幹細胞、多能性幹細胞、胚幹細胞、性腺幹細胞 、体幹/前駆細胞、造血幹細胞、表皮幹細胞、および神経幹細胞から選択される 、請求項1に記載の方法。 3.前記細胞供給源が陽性選択マーカーを有する幹細胞を包含し、そして前記マ ーカーの発現が幹細胞の単離および/または富化および/または維持を可能にす るために用いられる、請求項1または2のいずれかに記載の方法。 4.前記所望の幹細胞以外の細胞での陰性選択マーカーの発現が、該所望の幹細 胞以外の細胞の細胞供給源を選択的に枯渇するために用いられる、請求項1〜3 のいずれかに記載の 方法。 5.前記選択マーカーが、外来遺伝子、細胞性遺伝子、および抗生物質耐性遺伝 子から選択される、請求項1〜4のいずれかに記載の方法。 6.前記抗生物質耐性遺伝子が細菌性ネオマイシン耐性遺伝子である、請求項5 に記載の方法。 7.前記選択マーカーが成長刺激遺伝子である、請求項1〜6のいずれかに記載 の方法。 8.前記成長刺激遺伝子が、オンコジーンまたはその誘導体である、請求項7に 記載の方法。 9.前記成長刺激遺伝子が、SV40ラージT抗原またはSV40ラージT抗原の誘導体 である、請求項7に記載の方法。 10.前記成長刺激遺伝子が、成長因子をコードする遺伝子、成長因子レセプタ ーをコードする遺伝子、シグナル形質導入分子をコードする遺伝子、および転写 因子をコードする遺伝子から選択される、請求項7に記載の方法。 11.前記選択マーカーが不死化遺伝子である、請求項1〜 5のいずれかに記載の方法。 12.前記不死化遺伝子が、ポリオーマラージT遺伝子、細胞死を阻止する遺伝 子、およびbc1-2遺伝子から選択される、請求項11に記載の方法。 13.前記所望の多能性細胞の単離および/または富化および/または増殖が、 該所望の多能性細胞以外の細胞の存在に依存し、そして両方の細胞型の同時の維 持が、一方または他方の細胞集団で選択マーカーの発現に依存し、それは該マー カーを自己発現しないこれらの細胞に隣接する細胞を助ける能力を有する、請求 項1〜5のいずれかに記載の方法。 14.前記選択マーカーが、HPRT、毒性産物をコードする遺伝子、自殺基質と組 合せて条件により活性な毒性遺伝子産物、および単純ヘルペスウイルスチミジン キナーゼ(HSV-TK)遺伝子である、請求項13に記載の方法。 15.前記細胞が2つの選択マーカーを含む、請求項1〜14のいずれかに記載 の方法。 16.前記選択マーカーの発現が、細胞供給源に導入する前に、該選択マーカー を発現構築物に作動可能に挿入することにより達成される、請求項1〜15のい ずれかに記載の方法。 17.前記選択マーカーの発現が、安定に組み込まれた構築物、エピソーム的に 維持され構築物、または一過的に維持された構築物の誘導から生じる、請求項1 〜16のいずれかに記載の方法。 18.前記選択マーカーの発現が、細胞供給源の内因性遺伝子に該選択マーカー を作動可能に挿入することから生じる、請求項1〜17のいずれかに記載の方法 。 19.前記選択マーカーが、トランスフェクション、リポフェクション、注入、 衝撃ミサイル、ウイルスベクター、エレクトロポレーション、または任意の他の 手段により、前記細胞へ導入される、請求項1〜18のいずれかに記載の方法。 20.前記細胞供給源が、単細胞または細胞株;稔性化卵母細胞;トランスジェ ニック動物;非トランスジェニック動物;胚、血液、または体組織由来の細胞; および細胞混合物から選択される、請求項1〜19のいずれかに記載の方法。 21.前記選択マーカーがトランスジェニック動物に取り込まれる、請求項1〜 20のいずれかに記載の方法。 22.前記選択マーカーが、遺伝子または遺伝子フラグメントが幹細胞および非 幹細胞で特異な活性である発現を調節す る遺伝子または遺伝子フラグメントに作動可能に連結される、請求項1〜21の いずれかに記載の方法。 23.前記選択マーカーに作動可能に結合し、そして選択マーカーの発現を調節 する遺伝子または遺伝子フラグメントが、細胞の発達の多能性段階に関連する、 請求項1〜22のいずれかに記載の方法。 24.前記遺伝子または遺伝子フラグメントが、発達している胚の多能性細胞で 活性である、請求項23に記載の方法。 25.前記遺伝子または遺伝子フラグメントが、初期外胚葉で活性である、請求 項23または24に記載の方法。 26.前記遺伝子または遺伝子フラグメントが、Oct4遺伝子の全てまたは一部分 である、請求項22〜25のいずれかに記載の方法。 27.前記遺伝子または遺伝子フラグメントが、Oct4プロモーターである、請求 項22〜26のいずれかに記載の方法。 28.前記選択マーカーがネオマイシンホスホトランスフェラーゼ遺伝子である 、請求項1〜27のいずれかに記載の方法。 29.前記遺伝子または遺伝子フラグメントが多能性造血細胞で活性である、請 求項22〜28のいずれかに記載の方法。 30.前記遺伝子または遺伝子フラグメントがCD34遺伝子の全てまたは一部分で ある、請求項29に記載の方法。 31.選択マーカー構築物を、幹細胞を含む細胞供給源に導入する工程を包含す る、請求項1〜30のいずれかに記載の方法であって、該選択マーカー構築物が 、前記特異な発現を提供する内因性遺伝子に作動可能に連結するために適応され ている、方法。 32.選択マーカー構築物を、幹細胞を含む細胞供給源に導入する工程を包含す る請求項1〜30のいずれかに記載の方法であって、前記選択マーカー構築物が 前記特異な発現を提供する1つまたはそれ以上の遺伝子または遺伝子フラグメン トに既に連結されている、方法。 33.動物幹細胞を選択的に単離および/または富化および/または増殖する方 法であって、選択マーカー構築物を、幹細胞を含む細胞供給源に導入する工程を 包含し、該選択マーカー構築物が遺伝子または遺伝子フラグメントに作動可能に 連結するかまたは既に連結されており、該遺伝子または遺伝子フラグメントが幹 細胞および所望の幹細胞以外の細胞で該 選択マーカーの特異な発現を提供し、そして該方法が適切な培養条件下で所望の 幹細胞の選択的な単離および/または富化および/または増殖を可能にする、方 法。 34.前記選択マーカーが発現を調節する遺伝子または遺伝子フラグメントに作 動可能に連結し、遺伝子または遺伝子フラグメントが幹細胞および非幹細胞で特 異な活性である、請求項33に記載の方法。 35.前記遺伝子または遺伝子フラグメントがOct4プロモーターである、請求項 34に記載の方法。 36.前記選択マーカーがネオマイシンホスホトランスフェラーゼ遺伝子である 、請求項33〜35のいずれかに記載の方法。 37.動物幹細胞を選択的に単離するおよび/または富化するおよび/または増 殖する方法であって、選択培養条件下で細胞供給源を培養する工程を包含し、該 細胞供給源が遺伝子マーカーを含む幹細胞を含むことで特徴づけられ、それによ り該遺伝子マーカーと関連した遺伝子産物が生産され、そして該培養条件下で所 望の幹細胞の選択的再生産を起こす、方法。 38.幹細胞の単離および/または富化および/または増殖を可能にするように 適切な選択培養条件下で培養され得る動物細胞であって、該細胞が選択マーカー を含むことで特徴付けられ、ここで(a)所望の幹細胞および(b)所望の幹細胞以外 の細胞で該選択マーカーの特異な発現が、所望の幹細胞の選択的な生存または成 長を起こすことを可能にする、動物細胞。 39.請求項38に記載の動物細胞であって、そして請求項1〜37のいずれか に記載の細胞の特徴を包含する、動物細胞。 40.請求項1〜37のいずれかに記載の方法により、幹細胞の単離および/ま たは増殖に適切な細胞供給源を包含する、トランスジェニック動物。 41.請求項1〜37のいずれかに記載の方法により得られる細胞を用いて生産 される、トランスジェニック動物。 42.前記選択マーカーを含む細胞を有する、請求項41に記載のトランスジェ ニック動物。 43.請求項41に記載のトランスジェニック動物の子孫であって、該子孫の細 胞が前記選択マーカーを包含しない、子孫。 44.請求項1〜31のいずれかに記載の細胞供給源としての使用に適切である ように、細胞の遺伝学的な改変に用いるためのベクターであって、該ベクターは 前記選択マーカーに対応する第一の遺伝子成分および第二の遺伝子成分を包含し 、該第二の遺伝子成分が、遺伝学的に改変された動物細胞で、該選択マーカーの 前記特異な発現を直接的にまたは非直接的に生じる、ベクター。 45.請求項44に記載のベクターであって、発現ベクターの形態であり、前記 第二の遺伝子成分が、(a)幹細胞および(b)所望の幹細胞以外の細胞で特異に活性 化される制御配列を含む、ベクター。 46.前記制御配列がOct4プロモーターである、請求項45に記載のベクター。 47.前記選択マーカーが抗生物質マーカーである、請求項46に記載のベクタ ー。 48.前記抗生物質マーカーがネオマイシンホスホトランスフェラーゼである、 請求項47に記載のベクター。 49.請求項44〜48のいずれかに記載のベクターであって、請求項1〜37 にいずれかに記載の方法で使用するため の細胞の遺伝学的改変に用いる場合にゲノムに組み込まれない、ベクター。 50.請求項44〜48のいずれかに記載のベクターであって、前記第二の遺伝 子成分が、前記第一の遺伝子成分の少なくとも一部分をゲノムに特異的に組み込 むことを可能にする配列を包含する、ベクター。 51.認識配列、eg loxPまたはFRT部位をさらに含む、請求項44〜50のいず れかに記載のベクターであって、部位特異的組換えを介して組み込まれた構築物 の続いての切除を可能にする、ベクター。 52.請求項1〜37のいずれかに記載の方法により得られる幹細胞を培養する 工程、および前記選択マーカーを続いて切除する工程を包含する、トランスジェ ニック動物を調製する方法。 53.トランスジェニック動物を調製する方法であって、該動物が、以下を包含 する幹細胞の単離および増殖に適切な細胞供給源を含む、方法: 胚盤胞を提供する工程; 該胚盤胞に動物細胞を導入する請求項38〜39のいずれかに記載の動物細胞 を提供する工程; レシピエントに胚盤胞を移す工程;および、胚をキメラ動物に発達させ、選択 マーカーの生殖系伝達を可能にする工程。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB939308271A GB9308271D0 (en) | 1993-04-21 | 1993-04-21 | Method of isolating and/or enriching and/or selectively propagating pluripotential animal cells and animals for use in said method |
GB9308271.7 | 1994-01-20 | ||
PCT/GB1994/000848 WO1994024274A1 (en) | 1993-04-21 | 1994-04-21 | Isolation, selection and propagation of animal transgenic stem cells |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2005195670A Division JP4518401B2 (ja) | 1993-04-21 | 2005-07-05 | 動物トランスジェニック幹細胞の単離、選択、および増殖 |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH09500004A true JPH09500004A (ja) | 1997-01-07 |
JP4015183B2 JP4015183B2 (ja) | 2007-11-28 |
Family
ID=10734236
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP52294394A Expired - Fee Related JP4015183B2 (ja) | 1993-04-21 | 1994-04-21 | 動物トランスジェニック幹細胞の単離、選択、および増殖 |
JP2005195670A Expired - Fee Related JP4518401B2 (ja) | 1993-04-21 | 2005-07-05 | 動物トランスジェニック幹細胞の単離、選択、および増殖 |
JP2007139498A Expired - Fee Related JP4512613B2 (ja) | 1993-04-21 | 2007-05-25 | 動物トランスジェニック幹細胞の単離、選択、および増殖 |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2005195670A Expired - Fee Related JP4518401B2 (ja) | 1993-04-21 | 2005-07-05 | 動物トランスジェニック幹細胞の単離、選択、および増殖 |
JP2007139498A Expired - Fee Related JP4512613B2 (ja) | 1993-04-21 | 2007-05-25 | 動物トランスジェニック幹細胞の単離、選択、および増殖 |
Country Status (13)
Country | Link |
---|---|
US (4) | US6146888A (ja) |
EP (1) | EP0695351B2 (ja) |
JP (3) | JP4015183B2 (ja) |
AT (1) | ATE187491T1 (ja) |
AU (1) | AU678233B2 (ja) |
CA (1) | CA2161089A1 (ja) |
DE (1) | DE69422034T2 (ja) |
GB (1) | GB9308271D0 (ja) |
IL (1) | IL109381A (ja) |
NZ (1) | NZ265090A (ja) |
SG (1) | SG41951A1 (ja) |
WO (1) | WO1994024274A1 (ja) |
ZA (2) | ZA942719B (ja) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002511246A (ja) * | 1998-04-14 | 2002-04-16 | ユニヴァーシティー オブ エディンバラ | 系列特異性細胞および前駆体細胞 |
JPWO2005080598A1 (ja) * | 2004-02-19 | 2007-08-30 | 伸弥 山中 | 体細胞核初期化物質のスクリーニング方法 |
JP2010522565A (ja) * | 2007-03-26 | 2010-07-08 | アメリカ合衆国 | 胚性幹細胞分化を調整する方法 |
EP2354227A1 (en) | 2001-05-31 | 2011-08-10 | Shinya Yamanaka | Genes with ES cell-specific expression |
JPWO2014119627A1 (ja) * | 2013-01-29 | 2017-01-26 | 国立大学法人 東京大学 | キメラ動物の作製方法 |
Families Citing this family (145)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9308271D0 (en) * | 1993-04-21 | 1993-06-02 | Univ Edinburgh | Method of isolating and/or enriching and/or selectively propagating pluripotential animal cells and animals for use in said method |
US5602301A (en) * | 1993-11-16 | 1997-02-11 | Indiana University Foundation | Non-human mammal having a graft and methods of delivering protein to myocardial tissue |
GB9401380D0 (en) * | 1994-01-25 | 1994-03-23 | Pharmaceutical Proteins Ltd | Embryonic cell isolation |
US7119248B1 (en) | 1994-04-12 | 2006-10-10 | Miltenyi Biotec Gmbh | Antibodies against epitopes with homology to self antigens, methods of preparation and applications thereof |
GB2318792B (en) * | 1995-08-31 | 2000-06-21 | Roslin Inst | Unactivated oocytes as cytoplast recipients for nuclear transfer |
US7696404B2 (en) | 1996-08-19 | 2010-04-13 | Advanced Cell Technology, Inc. | Embryonic or stem-like cell lines produced by cross species nuclear transplantation and methods for enhancing embryonic development by genetic alteration of donor cells or by tissue culture conditions |
US6245564B1 (en) | 1997-01-23 | 2001-06-12 | Cornell Research Foundation, Inc. | Method for separating cells |
US7125714B2 (en) * | 1997-02-05 | 2006-10-24 | Licentia Ltd. | Progenitor cell materials and methods |
US6482937B1 (en) | 1997-10-09 | 2002-11-19 | Biotransplant, Inc. | Porcine Oct-4 promoter |
AU1197699A (en) | 1997-10-23 | 1999-05-10 | Geron Corporation | Methods and materials for the growth of primate-derived primordial stem cells |
EP1056835A4 (en) * | 1998-02-27 | 2003-01-15 | Hampton Roads Medical College | DERIVATION OF CELLS AND TISSUES FROM THE PRE-STRAINED CELL STAGE FOR TRANSPLANTATION THERAPIES |
GB9809178D0 (en) * | 1998-04-29 | 1998-07-01 | Univ Edinburgh | Nuclear reprogramming of somatic cells |
AUPP362898A0 (en) | 1998-05-21 | 1998-06-11 | University Of Sydney, The | Xenobiotic induction of gene expression |
GB9819912D0 (en) * | 1998-09-11 | 1998-11-04 | Univ Edinburgh | Propagation and/or derivation of embryonic stem cells |
US6667176B1 (en) | 2000-01-11 | 2003-12-23 | Geron Corporation | cDNA libraries reflecting gene expression during growth and differentiation of human pluripotent stem cells |
US7410798B2 (en) | 2001-01-10 | 2008-08-12 | Geron Corporation | Culture system for rapid expansion of human embryonic stem cells |
US7413904B2 (en) | 1998-10-23 | 2008-08-19 | Geron Corporation | Human embryonic stem cells having genetic modifications |
US7531715B1 (en) | 1999-01-13 | 2009-05-12 | Ppl Therapeutics (Scotland) | Double nuclear transfer method and results thereof |
AU4023700A (en) * | 1999-03-22 | 2000-10-09 | University Of Georgia Research Foundation, Inc., The | Germline-competent avian cells |
EP1201759B1 (en) | 1999-07-14 | 2010-03-10 | Transgenic Inc. | Trap vector and gene trapping method by using the same |
US8252280B1 (en) | 1999-08-05 | 2012-08-28 | Regents Of The University Of Minnesota | MAPC generation of muscle |
US7015037B1 (en) | 1999-08-05 | 2006-03-21 | Regents Of The University Of Minnesota | Multiponent adult stem cells and methods for isolation |
US10638734B2 (en) | 2004-01-05 | 2020-05-05 | Abt Holding Company | Multipotent adult stem cells, sources thereof, methods of obtaining and maintaining same, methods of differentiation thereof, methods of use thereof and cells derived thereof |
ES2208024B1 (es) * | 1999-10-14 | 2005-10-01 | Universidad Miguel Hernandez | Un metodo para obtener in vitro celulas madre de individuos mamiferos adultos. |
IL149175A0 (en) | 1999-10-28 | 2002-11-10 | Univ Massachusetts | Gynogenetic or androgenetic production of pluripotent cells and cell lines, and use thereof to produce differentiated cells and tissues |
US7455983B2 (en) | 2000-01-11 | 2008-11-25 | Geron Corporation | Medium for growing human embryonic stem cells |
US6828145B2 (en) | 2000-05-10 | 2004-12-07 | Cedars-Sinai Medical Center | Method for the isolation of stem cells by immuno-labeling with HLA/MHC gene product marker |
US6607720B1 (en) | 2000-09-05 | 2003-08-19 | Yong-Fu Xiao | Genetically altered mammalian embryonic stem cells, their living progeny, and their therapeutic application for improving cardiac function after myocardial infarction |
US6534052B1 (en) | 2000-09-05 | 2003-03-18 | Yong-Fu Xiao | Cardiac function comprising implantation of embryonic stem cell in which differentiation has been initiated |
US6576464B2 (en) | 2000-11-27 | 2003-06-10 | Geron Corporation | Methods for providing differentiated stem cells |
US6921665B2 (en) * | 2000-11-27 | 2005-07-26 | Roslin Institute (Edinburgh) | Selective antibody targeting of undifferentiated stem cells |
AU2002247875B2 (en) * | 2000-11-27 | 2007-09-06 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Transfection of human embryonic stem cells |
US20020168763A1 (en) * | 2000-11-30 | 2002-11-14 | Yan Wen Liang | Isolated homozygous stem cells, differentiated cells derived therefrom, and materials and methods for making and using same |
IL156303A0 (en) | 2000-12-06 | 2004-01-04 | Robert J Hariri | Method of collecting placental stem cells |
US7311905B2 (en) | 2002-02-13 | 2007-12-25 | Anthrogenesis Corporation | Embryonic-like stem cells derived from post-partum mammalian placenta, and uses and methods of treatment using said cells |
KR20030088023A (ko) | 2001-01-02 | 2003-11-15 | 스템론 인크. | 미리 선별된 면역형 및(또는) 유전자형을 갖는 동형접합성간세포 군집의 제조 방법, 그로부터 유래된 이식에 적합한세포, 및 이들을 사용하는 재료 및 방법 |
AU2002216296A1 (en) * | 2001-01-04 | 2002-08-06 | Cancer Research Technology Limited | Isolation of epidermal stem cells by using the melanoma-associated chondroitin sulfate proteoglycan |
EP1491093B1 (en) * | 2001-02-14 | 2013-07-31 | ABT Holding Company | Multipotent adult stem cells, sources thereof, methods of obtaining and maintaining same, methods of differentiation thereof, methods of use thereof and cells derived thereof |
CA2856986C (en) * | 2001-02-14 | 2019-08-13 | Anthrogenesis Corporation | Post-partum mammalian placental stem cells for use in the treatment of neurological or renal diseases and disorders |
DE10144326B4 (de) * | 2001-09-10 | 2005-09-22 | Siemens Ag | Verfahren und System zur Überwachung eines Reifenluftdrucks |
WO2003027247A2 (en) | 2001-09-24 | 2003-04-03 | Sangamo Biosciences, Inc. | Modulation of stem cells using zinc finger proteins |
US7129034B2 (en) | 2001-10-25 | 2006-10-31 | Cedars-Sinai Medical Center | Differentiation of whole bone marrow |
WO2003066839A1 (en) * | 2002-02-05 | 2003-08-14 | Rappaport Family Institute For Research In The Medical Sciences | Lineage committed stem cells selected for telomerase promoter activity |
NZ534643A (en) * | 2002-02-13 | 2010-06-25 | Anthrogenesis Corp | Embryonic-like stem cells derived from post-partum mammalian placenta and uses and methods of treatment using said cells |
AU2003216822A1 (en) * | 2002-03-19 | 2003-10-08 | University Of Sheffield | Stem cell culture |
US7498171B2 (en) * | 2002-04-12 | 2009-03-03 | Anthrogenesis Corporation | Modulation of stem and progenitor cell differentiation, assays, and uses thereof |
JP2006500910A (ja) | 2002-04-18 | 2006-01-12 | アキュイティ ファーマシューティカルズ、インク. | Cnsと眼の標的遺伝子を特異的に調節するための手段と方法及びその同定法 |
EP1525308A4 (en) * | 2002-05-30 | 2006-11-02 | Celgene Corp | METHODS OF USING JNK OR MKK INHIBITORS TO MODULATE CELL DIFFERENTIATION AND TREAT MYELOPROLIFERATIVE DISORDERS AND MYELODYSPLASIC SYNDROMES |
US7148342B2 (en) | 2002-07-24 | 2006-12-12 | The Trustees Of The University Of Pennyslvania | Compositions and methods for sirna inhibition of angiogenesis |
ES2609292T3 (es) | 2002-08-21 | 2017-04-19 | Revivicor, Inc. | Animales porcinos que carecen de cualquier expresión de alfa 1,3 galactosiltransferasa funcional |
GB0222846D0 (en) | 2002-10-03 | 2002-11-06 | Choo Yen | Cell culture |
BR0316695A (pt) | 2002-11-26 | 2005-10-18 | Anthrogenesis Corp | Unidade citoterapêutica, kit para tratamento, método de tratamento de uma enfermidade, biblioteca de unidades citoterapêuticas e método de tratamento de um paciente |
WO2004063356A2 (en) * | 2003-01-13 | 2004-07-29 | Rao Mahendra S | Persistent expression of candidate molecule in proliferating stem and progenitor cells for delivery of therapeutic products |
CA2515108A1 (en) * | 2003-02-07 | 2004-08-26 | Wisconsin Alumni Research Foundation | Directed genetic modifications of human stem cells |
IL155783A (en) | 2003-05-05 | 2010-11-30 | Technion Res & Dev Foundation | Multicellular systems of multi-potential embryonic human stem cells and cancer cells and their use |
EP1641912B1 (en) | 2003-06-20 | 2016-04-27 | Axiogenesis Ag | Tissue modelling in embryonic stem (es) cell system |
US20050196864A1 (en) * | 2004-02-10 | 2005-09-08 | Goldman Steven A. | Induction and high-yield preparative purification of mesencephalic dopaminergic neuronal progenitor cells and dopaminergic neurons from human embryonic stem cells |
JP2007529278A (ja) | 2004-03-17 | 2007-10-25 | レビビコア, インコーポレイテッド | 機能的α1,3ガラクトシルトランスフェラーゼを欠く動物に由来する組織生成物 |
WO2005098425A1 (en) | 2004-04-07 | 2005-10-20 | Axiogenesis Ag | Non-invasive, in vitro functional tissue assay systems |
DE602005025106D1 (de) | 2004-05-11 | 2011-01-13 | Axiogenesis Ag | Methoden zur medikamentenaufspürung auf der basis von in vitro differenzierten zellen |
EP1598428A1 (en) | 2004-05-18 | 2005-11-23 | Georg Dewald | Methods and kits to detect Hereditary angioedema type III |
CA2568201C (en) | 2004-05-24 | 2013-07-30 | Universitat Zu Koln | Identification of ergothioneine transporter and therapeutic uses thereof |
EP1602926A1 (en) | 2004-06-04 | 2005-12-07 | University of Geneva | Novel means and methods for the treatment of hearing loss and phantom hearing |
CN103146649B (zh) | 2004-06-09 | 2018-05-22 | 爱丁堡大学管理处 | 神经干细胞 |
GB0505510D0 (en) * | 2004-06-09 | 2005-04-27 | Univ Edinburgh | Neural stem cells |
US20050277124A1 (en) | 2004-06-10 | 2005-12-15 | White Steven M | Cardiac conduction system cells and uses thereof |
JP2008507981A (ja) * | 2004-07-29 | 2008-03-21 | ステム セル イノベーションズ, インコーポレイテッド | 幹細胞の分化 |
US20080254002A1 (en) * | 2004-09-03 | 2008-10-16 | Edelberg Jay M | Bone Marrow Derived Oct3/4+ Stem Cells |
WO2006035741A1 (ja) * | 2004-09-29 | 2006-04-06 | Dainippon Sumitomo Pharma Co., Ltd. | Es細胞特異的発現遺伝子及びその利用 |
JP2008517608A (ja) | 2004-10-22 | 2008-05-29 | レビビコア, インコーポレイテッド | 遺伝子改変された免疫系を有する有蹄動物 |
KR20080030039A (ko) | 2005-06-22 | 2008-04-03 | 제론 코포레이션 | 인간 배아 줄기 세포의 현탁 배양 |
GB0515006D0 (en) * | 2005-07-22 | 2005-08-31 | Univ Nottingham | Reprogramming |
WO2007035213A2 (en) | 2005-08-09 | 2007-03-29 | Revivicor, Inc. | Transgenic ungulates expressing ctla4-ig and uses thereof |
EP1957633B1 (en) | 2005-10-13 | 2013-12-18 | Anthrogenesis Corporation | Immunomodulation using placental stem cells |
GB0526664D0 (en) | 2005-11-30 | 2006-02-08 | Plasticell Ltd | Method |
ES2703502T3 (es) | 2005-12-29 | 2019-03-11 | Celularity Inc | Poblaciones de células madre placentarias |
CA2633775A1 (en) | 2005-12-29 | 2007-07-12 | Anthrogenesis Corporation | Co-culture of placental stem cells and stem cells from a second source |
KR100785049B1 (ko) | 2006-01-11 | 2007-12-12 | 한국과학기술연구원 | 줄기세포로부터 배아체를 형성 및 성장시키는 방법 및 장치 |
GB0615327D0 (en) | 2006-03-30 | 2006-09-13 | Univ Edinburgh | Culture medium containing kinase inhibitors and uses thereof |
GB2436737B (en) | 2006-03-30 | 2008-07-09 | Univ Edinburgh | Culture medium containing kinase inhibitors,and uses thereof |
EP2024493B1 (en) * | 2006-05-31 | 2014-07-02 | Cellect Biotechnology Ltd. | Methods of selecting stem cells and uses thereof |
AU2007258744A1 (en) * | 2006-06-06 | 2007-12-21 | University Of Tennessee Research Foundation | Compositions enriched in neoplastic stem cells and methods comprising same |
AU2007287585B2 (en) | 2006-08-24 | 2013-08-29 | Basf Plant Science Gmbh | Isolation and characterization of a novel Pythium omega 3 desaturase with specificity to all omega 6 fatty acids longer than 18 carbon chains |
AU2007321928A1 (en) * | 2006-11-24 | 2008-05-29 | Regents Of The University Of Minnesota | Endodermal progenitor cells |
GB0700478D0 (en) * | 2007-01-10 | 2007-02-21 | Stem Cell Sciences Australia P | Assay for cell culture media and medium supplements |
WO2008089396A1 (en) * | 2007-01-19 | 2008-07-24 | Invitrogen Corporation | Compositions and methods for genetic manipulation and monitoring of cell lines |
RS52921B (en) | 2007-02-12 | 2014-02-28 | Anthrogenesis Corporation | TREATMENT OF INFLAMMATORY DISEASES USING PLACENTAL CELL CELLS |
EP2121902A4 (en) | 2007-02-23 | 2010-12-22 | Advanced Cell Tech Inc | HIGHLY EFFICIENT METHODS OF RENEWING DIFFERENTIATED CELLS AND GENERATING ANIMALS AND EMBRYONIC STEM CELLS FROM NEWLY PROGRAMMED CELLS |
EP1997639B1 (en) | 2007-05-31 | 2010-02-17 | Brother Kogyo Kabushiki Kaisha | Liquid-droplet ejecting apparatus |
EP2020418A1 (en) | 2007-08-01 | 2009-02-04 | Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) | Fluorescent GFP variant displaying highly increased fluorescence intensity without a spectral shift |
US9200253B1 (en) | 2007-08-06 | 2015-12-01 | Anthrogenesis Corporation | Method of producing erythrocytes |
KR20180107320A (ko) | 2007-09-28 | 2018-10-01 | 안트로제네시스 코포레이션 | 인간 태반 관류액 및 인간 태반-유래 중간체 천연 킬러 세포를 사용한 종양 억제 방법 |
US20090239217A1 (en) * | 2007-10-08 | 2009-09-24 | University Of Florida Research Foundation, Inc. | Stem-like cells in bone sarcomas |
EP2093564A1 (en) | 2008-02-25 | 2009-08-26 | Technische Universität Dresden Medizinische Fakultät Carl Gustav Carus | Method for distinguishing secretory granules of different ages |
CA2621155A1 (en) * | 2008-02-29 | 2009-08-29 | James Ellis | Stem cell expression cassettes |
EP2108704A1 (en) | 2008-04-07 | 2009-10-14 | Life & Brain GmbH | Androgenetic alopecia |
US20090328241A1 (en) | 2008-06-27 | 2009-12-31 | The Uab Research Foundation | Mitochondrial-nuclear exchanged cells, tissues, organs and animals |
EP2151502A1 (en) | 2008-07-30 | 2010-02-10 | Lohmann Tierzucht GmbH | Genetic variations associated with feather pecking behaviour in avians |
WO2010021715A1 (en) | 2008-08-20 | 2010-02-25 | Anthrogenesis Corporation | Treatment of stroke using isolated placental cells |
PE20110400A1 (es) | 2008-08-20 | 2011-06-22 | Anthrogenesis Corp | Composiciones mejoradas de celulas y metodos para preparar las mismas |
JP2012500792A (ja) | 2008-08-22 | 2012-01-12 | アンスロジェネシス コーポレーション | 胎盤細胞集団による骨欠損の治療のための方法および組成物 |
ES2548377T3 (es) | 2008-10-27 | 2015-10-16 | Revivicor, Inc. | Ungulados inmunodeprimidos |
NZ602455A (en) | 2008-11-19 | 2014-03-28 | Anthrogenesis Corp | Amnion derived adherent cells |
US20100125265A1 (en) * | 2008-11-20 | 2010-05-20 | Medtronic Vascular, Inc. | Cell Delivery System to Induce Cell Growth and Angiogenesis |
WO2010065834A1 (en) | 2008-12-04 | 2010-06-10 | Opko Ophthalmics, Llc | Compositions and methods for selective inhibition of pro-angiogenic vegf isoforms |
EP2269630A1 (en) | 2009-06-15 | 2011-01-05 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Novel anti-nematode therapies targetting STRM-1 |
MX2012000110A (es) | 2009-07-02 | 2012-04-02 | Anthrogenesis Corp | Metodo para producir eritrocitos sin celulas alimetadoras. |
EP2275442A1 (en) | 2009-07-06 | 2011-01-19 | Ludwig-Maximilians-Universität München | Detection and vizualization of the cell cycle in living cells |
US8354389B2 (en) | 2009-08-14 | 2013-01-15 | Regeneron Pharmaceuticals, Inc. | miRNA-regulated differentiation-dependent self-deleting cassette |
WO2011050251A1 (en) * | 2009-10-23 | 2011-04-28 | The Board Of Trustees Of The Leland Stanford Junior University | Induction of germ cells from pluripotent cells |
WO2011069091A1 (en) | 2009-12-04 | 2011-06-09 | Boston Biomedical Research Institute, Inc. | Method for cloning pluripotent stem cells |
WO2011069093A1 (en) | 2009-12-04 | 2011-06-09 | Boston Biomedical Research Institute, Inc. | Detecting and counting tissue-specific stem cells and uses thereof |
JP2013518108A (ja) | 2010-01-26 | 2013-05-20 | アントフロゲネシス コーポレーション | 胎盤幹細胞を用いる骨関連癌の治療 |
TW201902496A (zh) | 2010-04-07 | 2019-01-16 | 美商安瑟吉納西斯公司 | 利用胎盤幹細胞之血管新生 |
CA2795401A1 (en) | 2010-04-08 | 2011-10-13 | Anthrogenesis Corporation | Treatment of sarcoidosis using placental stem cells |
EP3358007A1 (en) | 2010-07-13 | 2018-08-08 | Celularity, Inc. | Methods of generating natural killer cells |
US9725689B2 (en) | 2010-10-08 | 2017-08-08 | Terumo Bct, Inc. | Configurable methods and systems of growing and harvesting cells in a hollow fiber bioreactor system |
WO2012092485A1 (en) | 2010-12-31 | 2012-07-05 | Anthrogenesis Corporation | Enhancement of placental stem cell potency using modulatory rna molecules |
CN103492576A (zh) | 2011-02-14 | 2014-01-01 | 雷维维科公司 | 用于血管化异种移植物及其衍生物的异种移植的遗传修饰的猪 |
WO2012166844A2 (en) | 2011-06-01 | 2012-12-06 | Anthrogenesis Corporation | Treatment of pain using placental stem cells |
SI2739740T1 (sl) | 2011-08-05 | 2019-12-31 | Regeneron Pharmaceuticals, Inc. | Humanizirane univerzalne lahkoverižne miši |
US9925221B2 (en) | 2011-09-09 | 2018-03-27 | Celularity, Inc. | Treatment of amyotrophic lateral sclerosis using placental stem cells |
EP2695893A1 (en) | 2012-08-09 | 2014-02-12 | Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt GmbH | Novel far red fluorescent protein |
US9809853B2 (en) | 2012-08-16 | 2017-11-07 | Brain Biotechnology Research And Information Network Ag | Calcium-activated chloride channel involved in human sweat formation |
AU2014215458A1 (en) | 2013-02-05 | 2015-08-13 | Anthrogenesis Corporation | Natural killer cells from placenta |
EP3068866B1 (en) | 2013-11-16 | 2018-04-25 | Terumo BCT, Inc. | Expanding cells in a bioreactor |
SG11201607118PA (en) * | 2014-02-26 | 2016-09-29 | Brigham & Womens Hospital | System and method for cell levitation and monitoring |
EP3613841B1 (en) | 2014-03-25 | 2022-04-20 | Terumo BCT, Inc. | Passive replacement of media |
EP3194581A4 (en) | 2014-09-15 | 2018-04-25 | Children's Medical Center Corporation | Methods and compositions to increase somatic cell nuclear transfer (scnt) efficiency by removing histone h3-lysine trimethylation |
CN106715676A (zh) | 2014-09-26 | 2017-05-24 | 泰尔茂比司特公司 | 按计划供养 |
WO2017004592A1 (en) | 2015-07-02 | 2017-01-05 | Terumo Bct, Inc. | Cell growth with mechanical stimuli |
CN105660543A (zh) * | 2016-02-24 | 2016-06-15 | 范健身 | 一种药用蚯蚓改性养殖添加剂的制备方法 |
CN105580779A (zh) * | 2016-02-24 | 2016-05-18 | 范健身 | 一种药用蚯蚓的改性养殖方法 |
CN105707013A (zh) * | 2016-02-24 | 2016-06-29 | 范健身 | 一种用于改性养殖药用蚯蚓的改性养殖添加剂 |
US11965175B2 (en) | 2016-05-25 | 2024-04-23 | Terumo Bct, Inc. | Cell expansion |
US11685883B2 (en) | 2016-06-07 | 2023-06-27 | Terumo Bct, Inc. | Methods and systems for coating a cell growth surface |
US11104874B2 (en) | 2016-06-07 | 2021-08-31 | Terumo Bct, Inc. | Coating a bioreactor |
US11624046B2 (en) | 2017-03-31 | 2023-04-11 | Terumo Bct, Inc. | Cell expansion |
EP3656841A1 (en) | 2017-03-31 | 2020-05-27 | Terumo BCT, Inc. | Cell expansion |
WO2020053808A1 (en) | 2018-09-12 | 2020-03-19 | Georg Dewald | Method of diagnosing vasoregulatory disorders |
WO2021247623A1 (en) * | 2020-06-01 | 2021-12-09 | President And Fellows Of Harvard College | Compositions and methods for optogenetic control |
EP4247151A1 (en) | 2020-11-20 | 2023-09-27 | Revivicor Inc. | Multi-transgenic pigs with growth hormone receptor knockout for xenotransplantation |
US12043823B2 (en) | 2021-03-23 | 2024-07-23 | Terumo Bct, Inc. | Cell capture and expansion |
AU2022347161A1 (en) | 2021-09-20 | 2024-04-04 | Revivicor, Inc. | Multitransgenic pigs comprising ten genetic modifications for xenotransplantation |
CN118272378A (zh) * | 2024-04-24 | 2024-07-02 | 呈诺再生医学科技(北京)有限公司 | 一种维持多能干细胞干性及清除其在所分化细胞中残留的方法 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ219392A (en) * | 1986-02-28 | 1989-05-29 | Smithkline Beckman Corp | Production of an immortalised primary cell line |
US5112767A (en) | 1988-03-04 | 1992-05-12 | University Of Southern California | Vectors with enhancer domains |
CA1341469C (en) * | 1988-08-04 | 2004-12-28 | Robert Lindsay Williams | In vitro propagation of embryonic stem cells |
US5399493A (en) * | 1989-06-15 | 1995-03-21 | The Regents Of The University Of Michigan | Methods and compositions for the optimization of human hematopoietic progenitor cell cultures |
EP0437576B1 (en) * | 1989-07-25 | 2002-07-03 | Cell Genesys, Inc. | Homologous recombination for universal donor cells and chimeric mammalian hosts |
GB9308271D0 (en) * | 1993-04-21 | 1993-06-02 | Univ Edinburgh | Method of isolating and/or enriching and/or selectively propagating pluripotential animal cells and animals for use in said method |
US6015671A (en) | 1995-06-07 | 2000-01-18 | Indiana University Foundation | Myocardial grafts and cellular compositions |
US5602301A (en) | 1993-11-16 | 1997-02-11 | Indiana University Foundation | Non-human mammal having a graft and methods of delivering protein to myocardial tissue |
-
1993
- 1993-04-21 GB GB939308271A patent/GB9308271D0/en active Pending
-
1994
- 1994-04-20 ZA ZA942719A patent/ZA942719B/xx unknown
- 1994-04-20 ZA ZA942720A patent/ZA942720B/xx unknown
- 1994-04-21 EP EP94913174A patent/EP0695351B2/en not_active Expired - Lifetime
- 1994-04-21 IL IL10938194A patent/IL109381A/xx not_active IP Right Cessation
- 1994-04-21 SG SG1995001827A patent/SG41951A1/en unknown
- 1994-04-21 JP JP52294394A patent/JP4015183B2/ja not_active Expired - Fee Related
- 1994-04-21 US US08/535,141 patent/US6146888A/en not_active Expired - Lifetime
- 1994-04-21 DE DE69422034T patent/DE69422034T2/de not_active Expired - Lifetime
- 1994-04-21 AU AU65426/94A patent/AU678233B2/en not_active Ceased
- 1994-04-21 AT AT94913174T patent/ATE187491T1/de not_active IP Right Cessation
- 1994-04-21 WO PCT/GB1994/000848 patent/WO1994024274A1/en active IP Right Grant
- 1994-04-21 NZ NZ265090A patent/NZ265090A/en not_active IP Right Cessation
- 1994-04-21 CA CA002161089A patent/CA2161089A1/en not_active Abandoned
-
2000
- 2000-03-30 US US09/537,562 patent/US6878542B1/en not_active Expired - Fee Related
-
2005
- 2005-03-21 US US11/084,154 patent/US7256041B2/en not_active Expired - Fee Related
- 2005-07-05 JP JP2005195670A patent/JP4518401B2/ja not_active Expired - Fee Related
-
2007
- 2007-05-25 JP JP2007139498A patent/JP4512613B2/ja not_active Expired - Fee Related
- 2007-08-01 US US11/832,165 patent/US7459600B2/en not_active Expired - Fee Related
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002511246A (ja) * | 1998-04-14 | 2002-04-16 | ユニヴァーシティー オブ エディンバラ | 系列特異性細胞および前駆体細胞 |
EP2354227A1 (en) | 2001-05-31 | 2011-08-10 | Shinya Yamanaka | Genes with ES cell-specific expression |
JPWO2005080598A1 (ja) * | 2004-02-19 | 2007-08-30 | 伸弥 山中 | 体細胞核初期化物質のスクリーニング方法 |
US7964401B2 (en) | 2004-02-19 | 2011-06-21 | Kyoto University | Screening method for somatic cell nuclear reprogramming substance affecting ECAT2 and ECAT3 |
JP2010522565A (ja) * | 2007-03-26 | 2010-07-08 | アメリカ合衆国 | 胚性幹細胞分化を調整する方法 |
US8617813B2 (en) | 2007-03-26 | 2013-12-31 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Methods for modulating embryonic stem cell differentiation |
JPWO2014119627A1 (ja) * | 2013-01-29 | 2017-01-26 | 国立大学法人 東京大学 | キメラ動物の作製方法 |
JP6279141B1 (ja) * | 2013-01-29 | 2018-02-14 | 国立大学法人 東京大学 | キメラ動物の作製方法 |
JP2018046833A (ja) * | 2013-01-29 | 2018-03-29 | 国立大学法人 東京大学 | キメラ動物の作製方法 |
JP2018082716A (ja) * | 2013-01-29 | 2018-05-31 | 国立大学法人 東京大学 | キメラ動物の作製方法 |
US10645912B2 (en) | 2013-01-29 | 2020-05-12 | The University Of Tokyo | Method for producing chimeric animal |
US11844336B2 (en) | 2013-01-29 | 2023-12-19 | The University Of Tokyo | Method for producing chimeric animal |
Also Published As
Publication number | Publication date |
---|---|
ZA942720B (en) | 1995-03-30 |
ZA942719B (en) | 1995-01-09 |
JP4518401B2 (ja) | 2010-08-04 |
IL109381A (en) | 2000-08-31 |
GB9308271D0 (en) | 1993-06-02 |
EP0695351B1 (en) | 1999-12-08 |
US7459600B2 (en) | 2008-12-02 |
CA2161089A1 (en) | 1994-10-27 |
IL109381A0 (en) | 1994-07-31 |
NZ265090A (en) | 1997-03-24 |
US7256041B2 (en) | 2007-08-14 |
SG41951A1 (en) | 1997-08-15 |
EP0695351A1 (en) | 1996-02-07 |
DE69422034D1 (de) | 2000-01-13 |
DE69422034T2 (de) | 2000-08-03 |
WO1994024274A1 (en) | 1994-10-27 |
JP4512613B2 (ja) | 2010-07-28 |
EP0695351B2 (en) | 2008-10-29 |
US6878542B1 (en) | 2005-04-12 |
AU678233B2 (en) | 1997-05-22 |
JP2005323609A (ja) | 2005-11-24 |
AU6542694A (en) | 1994-11-08 |
JP4015183B2 (ja) | 2007-11-28 |
JP2007252387A (ja) | 2007-10-04 |
US6146888A (en) | 2000-11-14 |
ATE187491T1 (de) | 1999-12-15 |
US20080026459A1 (en) | 2008-01-31 |
US20050196858A1 (en) | 2005-09-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4015183B2 (ja) | 動物トランスジェニック幹細胞の単離、選択、および増殖 | |
CA2128862C (en) | Homogenotization of gene-targeting events | |
JPH09500005A (ja) | 標的とされた発現特性に従う異種遺伝子の発現 | |
KR20050096974A (ko) | 인간 줄기 세포의 지시된 유전적 변형 | |
CA2395439A1 (en) | Controlling offspring's sex ratio by targeting transgenes onto the sex chromosomes | |
Fan et al. | Development of cell cultures with competency for contributing to the zebrafish germ line | |
Doetschman | Gene transfer in embryonic stem cells | |
US20050144659A1 (en) | Animals and cells containing a mutated alpha2delta gene | |
EP1319709A1 (en) | Disruption of the glutathione S-transferase-omega-1 gene | |
Lan et al. | Generation of a germ cell nuclear factor conditional allele in mice | |
MXPA94002851A (en) | Isolation, selection, and propagation of animal truncal cells, animals and genetically modified animal cells, and constructions for your production | |
EP1321034A1 (en) | Disruption of the phosphodieterase 10 gene | |
US20030121069A1 (en) | Disruption of the phosphodiesterase 10 gene | |
US20030051267A1 (en) | Targeted disruption of kinase suppressor of RAS | |
JPH1033087A (ja) | グルタミン酸トランスポーター遺伝子機能欠損非ヒト動物 | |
JP2003310261A (ja) | Redk遺伝子の破壊 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20040309 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20040526 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20040712 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20040909 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20050308 |
|
A72 | Notification of change in name of applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A721 Effective date: 20050328 |
|
RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20050328 |
|
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20050328 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050705 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20050818 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20060228 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20060530 |
|
A72 | Notification of change in name of applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A721 Effective date: 20060530 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20060530 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20060809 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060822 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20060822 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20070130 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070424 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20070828 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20070913 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100921 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110921 Year of fee payment: 4 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110921 Year of fee payment: 4 |
|
RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: R3D02 |
|
LAPS | Cancellation because of no payment of annual fees |